Business heads of three leading Indian firms from as many sectors - automaker Mahindra and Mahindra, consumer goods major Godrej and biotechnology firm Biocon - on Monday said they were looking at acquisitions in overseas markets as the rupee appreciation had made such plans a good-value proposition.
The Indian biotech sector continues to face an acute shortage of specialists. But now there is a ray of hope, interestingly from a dark story being narrated in the pharma and biotech sectors in the United States and Europe. The sector is seeing downsizing there. This has made scientists of Indian origin explore opportunities in India. "The shortage and the noticeable gap is in terms of discovery-led drug development," said Kiran Mazumdar Shaw, CMD, Biocon
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
India's export revenue from biotechnology grew by 47 per cent to reach to 1.2 billion dollars in the financial year ended March 2007, a survey said.
R C Bhargava, Kiran Mazumdar-Shaw & Dinesh K Sarraf are other members of the business delegation
In a recent awards event, industrialist Rahul Bajaj said that India Inc was afraid of criticising the Narendra Modi government, The comment drew flak from Finance Minister Nirmala Sitharam who said spreading one's own impression "can hurt national interest".
The government on Wednesday granted approval to Nokia, Wipro, Hewlett Packard, Reliance, Biocon, Ranbaxy Laboratories, Mahindra and Mahindra, Reliance energy and Adani Group's to set up Special Economic zones.
Today, an engineer from an average college can easily land an IT job. What about the biotech graduate, asks Rashmi Bansal?
Bengaluru's celebs wish the newly-weds.
Competing with established biotech companies in India such as Wockhardt, Biocon and Reliance Life Sciences, small biotech companies such as Zenotech, BV Biocorp and Intas Biopharma are likely to emerge as major players in biogeneric drugs.
Researchers and scientists in India would have to be innovative if the country wished to unleash its vast intellectual potential, chairman and managing director of Biocon Ltd Kiran Mazumdar Shaw said on Saturday.
Addressing aspiring entrepreneurs, Biocon Chief Shaw adviced them never to fear failure.
Utility vehicles manufacturer Mahindra & Mahindra will replace Hero Honda in the country's benchmark index Sensex from July 9.
Kiran Mazumdar-Shaw, chairman and managing director of Biocon, Chanda Kochar, executive director of ICICI Bank and Vidya Chhabria, chairman of Jumbo Group
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Others in the top 10 include Uday Kotak at the 6th place with a wealth of Rs 94,100 crore, Cyrus S Poonawalla at 7th position with Rs 88,800 crore assets, Cyrus Pallonji Mistry at 8th spot with a wealth of Rs 76,800 crore, Shapoor Pallonji at 9th position with a net worth of Rs 76,800 crore and Dilip Shanghvi at 10th slot with Rs 71,500-crore wealth.
Sitharaman, who is not known to reply to comments made on her Twitter handle, instantly choose to respond to drug-maker Biocon chairman Kiran Mazumdar-Shaw's criticism of lack of fiscal measures to support growth.
The government on Monday approved the proposals of Reliance Industries, Wipro, Hewlett Packard and Biocon to set up Special Economic Zones -- a move that is expected to generate at least 67,000 jobs by March 2006.
Three Indian women -- ICICI Bank deputy managing director Chanda Kochhar, HSBC India CEO Naina Lal Kidwai and Biocon head Kiran Mazumdar-Shaw -- have been named among the world's 50 most powerful businesswomen by the Fortune magazine.
The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.
Bharti Airtel Chairman Sunil Bharti Mittal said India has lost one of the finest political leaders and a legal luminary.
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
Earlier, Jaslok Hospital had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As Covid-19 cases surge in India, companies have realised it's a tightrope walk between maintaining production and ensuring employee safety.
Bureaucratic delays are stifling growth in the sector. India should be far more aggressive in launching 'look alike' biological molecules in a fast track manner.
Domestic pharma giant Ranbaxy Laboratories Limited has topped the list of patent filers in the area of drug applications from the Third World countries last year with 64 new formulations.\n\n\n\n
The BSE Mid-Cap index was currently up 0.83%. The BSE Small-Cap index was currently up 0.8%.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Narayan Murthy says the software industry has boosted the international image of India like no other sector.